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Abstract
Background: Single nucleotide polymorphisms (SNPs) in chitinase 3-like 1 (CHI3L1), the gene encoding YKL-40, and
increased serum YKL-40 levels are associated with severe forms of asthma. It has never been addressed whether
SNPs in CHI3L1 and cord blood YKL-40 levels could already serve as potential biomarkers for milder forms of asthma.
We assessed in an unselected population whether SNPs in CHI3L1 and cord blood YKL-40 levels at birth are associated
with respiratory symptoms, lung function changes, asthma, and atopy.
Methods: In a prospective birth cohort of healthy term-born neonates (n = 260), we studied CHI3L1 polymorphisms,
and measured cord blood YKL-40 levels by ELISA in (n = 170) infants. Lung function was performed at 5 weeks and 6
years. Respiratory health during the first year of life was assessed weekly by telephone interviews. Diagnosis of asthma
and allergic sensitisation was assessed at 6 years (n = 142).
Results: The SNP rs10399805 was significantly associated with asthma at 6 years. The odds ratio for asthma was 4.5
(95 % CI 1.59–12.94) per T-allele. This finding was unchanged when adjusting for cord blood YKL-40 levels. There
was no significant association for cord blood YKL-40 levels and asthma. SNPs in CHI3L1 and cord blood YKL-40
were not associated with lung function measurements at 5 weeks and 6 years, respiratory symptoms in the first
year, and allergic sensitisation at 6 years.
Conclusion: Genetic variation in CHI3L1 might be related to the development of milder forms of asthma. Larger
studies are warranted to establish the role of YKL-40 in that pathway.
Keywords: Asthma, CHI3L1 protein, Children, Cohort study, Cord blood, Genetic association study, Genetic variation,
Infants, YKL-40 protein
Background
The incidence of childhood asthma is increasing [1], and
early identification of infants at risk could help in the
prevention and treatment of this disease. Several studies
have proposed that the recently discovered biomarker
YKL-40 could be useful in the diagnosis of asthma [2].
The chitinase-like protein, YKL-40, is secreted by mac-
rophages, neutrophils and epithelial cells: particularly in
people with severe asthma [3, 4]. In serum, YKL-40
was elevated in children and adults with severe
asthma [5–7], and inversely correlated with lung func-
tion measures [6, 7]. It was recently suggested that
YKL-40 could be involved directly in airway remodel-
ing [4, 5, 8]. Genetic studies revealed that variation in
the gene encoding YKL-40, chitinase 3-like 1 (CHI3L1),
contributes to the pathogenesis of asthma [6]. Genetic
variation in CHI3L1 was associated with pathological
lung function values in adults [6], and correlated with
poor asthma control and inflammatory markers in se-
vere asthmatic children [5].
Direct involvement of YKL-40 in airway remodeling
[4, 5, 8] lead us to hypothesise that early measurement
of YKL-40 levels might help identify infants at risk for
asthma. Until now, only one longitudinal study in high-
risk asthmatic children assessed single nucleotide poly-
morphisms (SNPs) in CHI3L1 and cord blood YKL-40
levels at birth. The authors identified genotype-specific
effects on circulating YKL-40 levels, but no association
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of SNPs in CHI3L1 and cord blood YKL-40 with asthma
at school age was found [6]. It remains unknown if gen-
etic variations in CHI3L1 or cord blood YKL-40 levels
assessed at birth in unselected infants are associated
with milder forms of childhood asthma.
We studied in a birth cohort of unselected infants the as-
sociation of SNPs in CHI3L1 and cord blood YKL-40 levels
with asthma development. We further assessed the correl-
ation of SNPs in CHI3L1 and cord blood YKL-40
levels with respiratory symptoms in the first year of
life, lung function measures, and allergic sensitisation.
Methods
Methods are detailed in Additional file 1.
Study design and subjects
This prospective birth cohort study comprised a group
of unselected, healthy neonates recruited antenatally in
the region of Bern, Switzerland. The Ethics Committee
of the region of Bern approved the study, and written
consent from all parents was acquired at enrolment.
Genotyping and marker selection
Genome-wide SNP genotyping was conducted in collabor-
ation with asthmagene.de (University of Regensburg,
Germany) using Illumina HumanOmniExpress Bead Chips
(Illumina Inc., San Diego, USA) according to the manufac-
turer’s instructions. Details on genotyping and quality con-
trol methods are given in the online supplement. SNPs from
a region 13 kb upstream and 1.2 kb downstream of CHI3L1
were chosen, as previously described [9]. The SNPs selection
was done on HapMap CEU data (www.hapmap.org) PhaseII
+ III Rel28 10th of August 2015, on NCBI B36 assembly,
dbSNP b126. Haploview [10] was used to calculate linkage
disequilibrium (LD) and to select tagging SNPs with a minor
allele frequency (MAF) >5 % and r2 > 0.8. In total 7 SNPs
were represented on the Chip and included in the analysis
(Fig. 1).
Fig. 1 Linkage disequilibrium (LD) map of the CHI3L1 gene region based on D’ and logarithm of odds [5] score values. D’ values are shown inside
each diamond. Red diamonds indicate high LD, pink (D’ <1 and LOD ≥2), white (D’ <1 and LOD <2) and blue (D’ =1 and LOD <2). The black
triangles show the LD-blocks calculated by Haploview. The plot was created using HapMap data (CEU)
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YKL-40 measurement
Cord blood YKL-40 was measured in duplicates by an
enzyme-linked immunosorbent assay (ELISA) (R&D
Systems, USA). In order to capture the elevated cord
blood YKL-40 levels with the limited range of the
ELISA, samples had to be pre-diluted 1:20 before
measurement. For consistency, all samples were pre-
diluted at the same ratios. Data is presented as ng/ml;
minimum detection limit of the assay is 3.55 pg/ml.
Outcomes during the first year
Respiratory symptoms were assessed weekly by tele-
phone interviews [11, 12]. Lung function was performed
according to ERS/ATS standards [13]. Tidal volume
(VT), mean tidal expiratory flow, time to peak tidal
expiratory flow (TPTEF)/expiratory time (TE) ratio and
minute ventilation (V’E) were measured (Exhalyzer D;
Eco Medics AG, Duernten, Switzerland).
Outcomes at 6 years
Respiratory health was assessed using questions from
the International Study of Asthma and Allergies in
Childhood [14]. Asthma was diagnosed if one on the fol-
lowing was present in the previous year: (1) physician
diagnosis of asthma or (2) episodic wheeze. Atopy was
defined by allergic rhinitis, allergic asthma, or atopic
dermatitis. A skin-prick test was done for the following
allergens: (Dog dander, cat dander, Dermatophagoides
pteronyssinus, mixed tree pollens, mixed grass pollens,
Alternaria tenuis, positive control (histamine), negative
control (NaCl), Allergomed, Switzerland) positive in case
of hives bigger than histamine in any of the tested aller-
gens. Forced expiratory volume in 1 s (FEV1), forced
vital capacity (FVC) and forced expiratory flow at 25–75
% of FVC (FEF25–75%) was measured according to ATS
standards [15]. Data are expressed as z-scores using nor-
mative data from the Global Lung Function Initiative [16].
Risk factors
Exposure to pre- and postnatal risk factors [11, 14, 17]
on outcomes are given in Additional file 1: Table S1. We
validated maternal smoking by cotinine levels in the first
urine of the newborn (gas–liquid chromatography, IST,
Lausanne, Switzerland). Maternal asthma (self-reported
or doctor-diagnosed), maternal atopic disease (history
of allergic rhinitis, allergic asthma or atopic derma-
titis), and parental education were assessed.
Statistical analysis
Anthropometric and clinical outcomes were compared
with t-test and Mann–Whitney U-test. We conducted
Poisson, logistic and linear regression analysis. For re-
gression models, associations were calculated: (a) un-
adjusted and, (b) adjusted for known and potential
confounders. YKL-40 was categorised in quintiles and
associations of YKL-40 levels were calculated using
the Cochran-Armitage trend test, shown as Ptrend. A
trend of association was defined for Ptrend <0.2. We
used an additive genetic model and corrected for multiple
comparisons according to Benjamini-Hochberg [18]. A
P-value <0.05 was considered significant. Data was
analysed with STATA®, R [19], PLINK [20]. Power
was calculated with Quanto [21].
Results
From 1999 to 2007 the study enrolled n = 260 in-
fants with genotyping performed in n = 225. After
genetic quality control and exclusion of individuals
without YKL-40 measurements, n = 170 remained
for analysis. Of these, n = 28 children were lost to
follow-up resulting in n = 142 school-aged children
(Additional file 1: Figure S1). Population character-
istics and clinical outcomes are given in Table 1
(equally distributed by sexes), and possible risk fac-
tors in Additional file 1: Table S1. Characteristics of
the SNPs are shown in Additional file 1: Table S2.
None of the SNPs were associated with cord blood
YKL-40 levels (Additional file 1: Table S3).
Outcomes during the first year
SNPs and cord blood YKL-40 levels were neither asso-
ciated with ‘any respiratory symptoms’ nor with ‘severe
respiratory symptoms’ during the first year of life in
the univariable analysis. When adjusting for potential
confounders on respiratory symptoms [12] this asso-
ciation remained non-significant (Additional file 1:
Table S4). Associations between SNPs and cord blood
YKL-40 with lung function at 5 weeks are given in
Additional file 1: Table S5. There was no association
in either the univariable or adjusted models for any of
the examined parameters. Sensitivity analysis with
adjustment for e.g. maternal asthma and delivery type
revealed similar results (data not shown).
Outcomes at 6 years
At follow-up, there were 76 (53 %) males, 15 (11 %)
asthmatics, 18 (17 %) had a positive prick test and 53
(39 %) were atopic. The SNP rs10399805 [T] was signifi-
cantly associated with asthma at 6 years (Benjamini-
Hochberg adjusted P = 0.031). The odds ratio (OR) for
asthma was 4.5 (95 % CI 1.59–12.94) per T-allele in the
univariable assocation. This study was sufficiently pow-
ered (80 %) at the 5 % level of significance for an OR >4.
When adjusting for maternal atopy, parental smoking
and parental education, this association was non-
significant (Table 2). A protective effect of the A-allele
of rs10399931 for asthma and atopy in the adjusted
model [OR asthma 0.21 (95 % CI 0.04–0.98), OR atopy
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0.43 (95 % CI 0.21–0.86)] was observed. These results
were non-significant when adjusting for multiple
comparisons (Table 2). Since asthma is known to be
associated with YKL-40 levels (5, 6), we adjusted the
associations of SNPs with asthma for cord blood YKL-40
levels, which revealed similar results (Table 3). This indi-
cates that YKL-40 does not seem to be involved in the
pathway responsible for the observed association
between SNPs and asthma (Fig. 2). Positive prick test
results were not associated with any of the SNPs in the
uni- and multivariable analysis (Additional file 1: Table
S6).
We observed a trend of association of YKL-40 levels
with the OR for asthma and positive prick test results
(Ptrend = 0.169) (Table 2, Fig. 3 and Additional file 1:
Table S6). Associations of SNPs and cord blood YKL-
40 levels with lung function measures are given in
Additional file 1: Table S7. There was no association
in the univariable or adjusted models for any of the
examined parameters.
Discussion
Summary
In this cohort study, we examined the effect of genetic
variation of CHI3L1 and cord blood YKL-40 levels of un-
selected infants. We demonstrate that genetic variation of
CHI3L1 is associated with asthma in early childhood. In
particular, the T-allele of rs10399805 significantly
Table 1 Population characteristics and distribution of clinical outcomes
Mean ± S.D. Median (IQR) Range N (%)
Anthropometrics at birtha
Gestational age weeks 39.7 ± 1.1 40 (39.1–40.7) 37.0–42.0
Weight kg 3.4 ± 0.4 3.4 (3.1–3.7) 2.2–4.9
Length cm 49.5 ± 1.9 50.0 (48–51) 45–55
Anthropometrics at follow-upa
Age years 6.0 ± 0.3 6 (5.9–6.2) 5.1– 6.9
Weight kg 22.7 ± 3.8 22.2 (20.0–24.5) 16–35.8
Length cm 117.5 ± 5.6 117.5 (114–121) (104–107)
YKL-40 in cord blooda
YKL-40 ng/ml 42.4 ± 28.0 43.5 (23.3–63.3) 0–97.2
Clinical outcomes during the first yeara
Wks with daytime resp. sympt. 4.6 ± 4.6 3 (1–7) 0–24
Wks with nighttime resp. sympt. 3.8 ± 3.8 3 (1–6) 0–21
Wks with severe daytime resp. sympt. 0.5 ± 0.9 0 (0–1) 0–5
Wks with severe nighttime resp. sympt. 0.6 ± 1.1 0 (0–1) 0–8
Lung function at 5 weeksa
Tidal volume ml 32.5 ± 5.5 32.5 (28.1–36.4) 21–51
Mean tidal expiratory flow 43.3 ± 10.4 41.6 (35.7–49.3) 21–79
TPTEF/TE 36.2 ± 10.8 34.7 (28.7–41.8) 16–73
Minute Ventilation ml · min−1 1427 ± 270 1405 (1239–1586) 870–2333
Clinical data at 6 years
Asthmab 15 (12 %)
Atopyc 53 (39 %)
Positive prick testd 18 (17 %)
Lung function at 6 years
FVC z-scoree −0.41 ± 0.98 −0.04 (−1.18–0.32) −2.25–2.02
FEV1 z-score
f −0.09 ± 0.96 −0.21 (−0.83–0.73) −0.25–2.02
FEF25–75% z-score
g −0.04 ± 0.94 −0.04 (−0.68–0.55) −2.95–2.27
FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity, FEF25–75% Forced expiratory flow at 25–75 % of FVC, IQR Interquartile range, N Number, S.D. Standard
deviation, Wks Weeks, resp. sympt Respiratory symptoms. Data are given as mean (S.D.) median (IQR) or number (percentage) of infants. aData on = 142 infants.
bMissing data on n = 7; data available for n = 135. cMissing data on n = 4; data available for n = 138. dMissing data on n = 38; data available for n = 104. eMissing data
on n = 51; data available for n = 91. fMissing data on n = 66; data available for n = 76. gMissing data on n = 62; data available for n = 80
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increased the risk for asthma, even after correction for
multiple testing. Cord blood YKL-40 levels were not asso-
ciated with any of the investigated outcomes.
Limitations and strenghts
The main limitation is the small sample size, which re-
stricts power to identify weak associations. However, in
contrast to previous cross-sectional studies [5, 9, 22, 23],
this study was conducted in a cohort with a highly elab-
orate design, which naturally limits sample size. Unlike a
previous prospective study [6], we diagnosed asthma
based on one definition and assessed further outcomes
on respiratory health (lung function at 5 weeks and 6
years, respiratory symptoms during the first year).
Nevertheless, most of the correlations in this study
were negative and only some findings indicated a trend
of association. Trends of associations might be
rendered to significant findings with more asthma
cases. In an unselected population, this could be
achieved by increasing the sample size or by studying a
Table 2 Associations between cord blood YKL-40 levels and SNPs with asthma and atopy at school age
Univariable association Multivariablea association
OR 95 % CI P-value OR 95 % CI P-value
Exposure Outcome asthmab
SNP*
rs10920579 0.25 0.06–1.15 0.305 0.23 0.05–1.2 0.365
rs880633 1.33 0.63–2.89 0.777 1.05 0.46–2.38 0.901
rs10399931 0.21 0.05–0.95 0.212 0.21 0.04–0.98 0.287
rs10399805 4.50 1.59–12.94 0.031 3.42 1.12–10.56 0.224
rs1538372 0.74 0.31–1.72 0.777 0.68 0.28–1.63 0.901
rs7542294 2.80 1.29–7.01 0.158 2.37 0.87–6.46 0.365
rs2486064 0.89 0.42–1.91 0.777 0.94 0.42–2.19 0.901
YKL-40 (ng/ml)
YKL-40 non-detects 1 reference Ptrend 1 reference Ptrend
YKL-40 (7–37.9) 0.86 0.13–5.54 0.82 0.12–5.67
YKL-40 (38–49.9) 1.21 0.22–6.43 1.45 0.24–8.61
YKL-40 (50–65.9) 1.72 0.35–8.38 2.27 0.41–12.2
YKL-40 (66–98) 2.24 0.49–10.24 0.218** 2.52 0.49–13.01 0.169**
Exposure Outcome atopyc
SNP*
rs10920579 0.56 0.26–1.14 0.691 0.50 0.24–1.05 0.714
rs880633 0.92 0.55–1.51 0.96 0.94 0.57–1.56 0.913
rs10399931 0.45 0.24–0.91 0.169 0.43 0.21–0.86 0.251
rs10399805 1.43 0.64–3.19 0.96 1.63 0.71–3.75 0.913
rs1538372 0.83 0.48–1.39 0.96 0.81 0.47–1.39 0.913
rs7542294 1.25 0.62–2.55 0.96 1.37 0.66–2.81 0.913
rs2486064 0.98 0.61–1.59 0.96 0.89 0.54–1.47 0.913
YKL-40 (ng/ml)
YKL-40 non-detects 1 reference Ptrend 1 reference Ptrend
YKL-40 (7–37.9) 1.15 0.42–3.13 1.09 0.43–3.21
YKL-40 (38–49.9) 1 0.37–2.67 0.98 0.37–2.71
YKL-40 (50–65.9) 1.44 0.54–3.83 1.35 0.55–3.91
YKL-40 (66–98) 1.76 0.67–4.61 0.188** 1.69 0.66–4.58 0.232**
CI Confidence interval, OR Odds ratio. SNP Single nucleotide polymorphism. Cord blood YKL-40 levels are compared with YKL-40 non-detects. aAdjusted for the
following additional risk factors: sex, parental smoking during childhood, maternal atopy, parental education. bAsthma was diagnosed if one on the following was
present in the previous year: (1) physician diagnosis of asthma or (2) episodic wheeze. Missing data on n = 7; data available for n = 135. cDefined if one of the
following was present: asthma, allergic rhinitis, atopic eczema or positive prick test. Missing data on n = 4; data available for n = 138. *P-values for SNPs are shown
after correction for multiple testing according to Benjamini-Hochberg. **Ptrend-values were calculated with the Cochran-Armitage trend test
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high-risk population. Both options have their draw-
backs since larger birth cohort studies with a similar
elaborate design are lacking, while studies in high-risk
populations are predominantly multi-center studies,
introducing a bias on asthma diagnosis due to different
study sites.
Associations between genetic variation in CHI3L1
and asthma are controversial in the discussion, and the
Table 3 Associations between SNPs and asthma at school age adjusted for cord blood YKL-40 levels
Univariable association Univariable association
adjusted for YKL-40 levels
OR 95 % CI P-value OR 95 % CI P-value
Exposure Outcome asthmaa
SNP*
rs10920579 0.25 0.06–1.15 0.305 0.23 0.05–1.08 0.254
rs880633 1.33 0.63–2.89 0.777 1.27 0.59–2.75 0.654
rs10399931 0.21 0.05–0.95 0.212 0.2 0.04–0.89 0.189
rs10399805 4.50 1.59–12.94 0.031 4.76 1.66–13.62 0.026
rs1538372 0.74 0.31–1.72 0.777 0.71 0.31–1.68 0.654
rs7542294 2.80 1.29–7.01 0.158 2.66 1.06–6.72 0.189
rs2486064 0.89 0.42–1.91 0.777 0.84 0.39–1.81 0.654
CI Confidence interval, OR Odds ratio. SNP Single nucleotide polymorphism. aAsthma was diagnosed if one on the following was present in the previous year:
(1) physician diagnosis of asthma or (2) episodic wheeze. Missing data on n = 7; data available for n = 135. *P-values for SNPs are shown after correction for
multiple testing according to Benjamini-Hochberg
Fig. 2 Schematic presentation of associations of genetic polymorphisms in the CHI3L1 gene (rs10399805) and cord blood YKL-40 levels with
asthma at 6 years. Coef: coefficient; CI: confidence interval; OR: odds ratio. There was no association of rs10399805 with cord blood YKL-40 levels,
nor an association between YKL-40 and asthma at 6 years. In the unadjusted analysis, the SNP rs10399805 was associated with asthma at 6 years,
even after adjustment for YKL-40 levels (Table 3). The continuous line represents the mean. Data are derived from n = 135 children with n = 15
with asthma diagnosis
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SNP rs4950928 has been extensively studied in this
context. While a study in Korean children found no
association of rs4950928 with asthma [23], other stud-
ies reported conflicting findings on the suspected risk
allele of rs4950928 and asthma [6, 9, 22]. In a Danish
study of adults, Rathcke et al. [22] found that homozy-
gosity of the G allele was associated with asthma, while
Ober et al. [6] found a higher prevalence of the C allele
to be associated with asthma in three different popula-
tions (genetically related subjects, children recruited in
Germany and a mixed population of children and
adults). Interestingly, in a study performed in adults at in-
creased risk for asthma [9], the rs4950928 polymorphism
was not associated with airflow obstruction, indicating
that severity of asthma is not modified by this polymorph-
ism. It is a weakness that rs4950928 was not genotyped in
our study and that we cannot conclude on associations
between this extensively studied tag SNP in CHI3L1 and
asthma development. However, we investigated
rs10920579, which was in high linkage disequilibrium with
the SNP rs4950928 (r2 = 1), and therefore serves as a good
tagging SNP for the genetic variation associated with
asthma at this locus. Moreover, we performed analysis of
associations with 6 other SNPs in the CHI3L1 gene region,
and these results support the overall conclusions of our
study. Nevertheless, we are unable to determine if the ef-
fect of genetic variation of CHI3L1 on current asthma is
reflected by current YKL-40 levels, as YKL-40 levels were
not measured at 6 years.
A major strength is our use of a rigorous method-
ology in the assessment of respiratory symptoms and
lung function measurements. We studied the association
of genetic variation of CHI3L1 and cord blood YKL-
40 levels with respiratory morbidity at various time
points in unselected infants. Applicability of these re-
sults is not limited to high-risk subjects, as investi-
gated previously [6], but extend as well to the general
population.
The observed asthma prevalence of 11 % in this study
represents well the general population prevalence in
Switzerland, as reported from larger cross-sectional
studies [24]. Most of the asthmatics in this study belong
to the episodic wheezing phenotype, and multiple trigger
wheezing phenotypes are rarely found in this cohort
of unselected infants. Diagnosing asthma in paediatric
subjects is challenging, resulting in underdiagnosed
cases [24]. Even though rigorous assessment of asthma
diagnoses by study physicians was performed in this
cohort with validated questionnaires [25], there remains a
risk that some asthmatics were not correctly identified.
Since the observed prevalence of asthmatic subjects is
in concordance with the published prevalence in this
region [24], we however consider the number of false
negative diagnoses to be low.
Comparison with literature
SNPs in CHI3L1 and cord blood YKL-40 levels
We did not find any associations of the investigated
SNPs with cord blood YKL-40 levels. This contradicts
previous publications, describing an association of
rs4950928 with cord blood YKL-40 levels (6). Interest-
ingly, in contrast to previous publications (6), we had
21 % measurements below detection limit. The differ-
ent distribution of YKL-40 levels in our cohort of unse-
lected infants compared to YKL-40 levels in high-risk
asthmatic subjects (6) might account for the lack of
association of genetic variation of CHI3L1 and cord
blood YKL-40 levels. This hypothesis, however, requires
validation in a larger sample.
Respiratory symptoms and asthma
There was no association of any of the investigated
SNPs and cord blood YKL-40 levels with respiratory
symptoms during the first year, a subject that has not
been addressed in previous studies. The association of
genetic variation of CHI3L1 and asthma, however, has
been well documented in large European populations
studies [4, 9], while other authors suggested no associ-
ation of polymorphisms in CHI3L1 with asthma [26].
We identified a thus far unreported association be-
tween rs10399805 and asthma at 6 years. Moreover,
rs10399805 was not associated with cord blood YKL-40
levels (Additional file 1: Table S3) and cord blood YKL-40
levels did not modify the association of rs10399805
with asthma (Table 3). Thus, from our data we speculate
that rs10399805 is more relevant for asthma development
Fig. 3 Associations between cord blood YKL-40 levels and asthma at
6 years. CI: confidence interval; log: logarithmic; OR: odds ratio. Data
is given as OR (with 95 % CI) for asthma at 6 years for 4 different
categories of cord blood YKL-40 levels above detection limit. YKL-40
non-detects (not shown) served as reference. Data are derived from
n = 135 children with n = 15 with asthma diagnosis. The combined
P–value for trend for the adjusted OR was (Ptrend = 0.169)
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than cord blood YKL-40 levels in unselected infants
(Fig. 2). When adjusting for potential risk factors, this
association did not reach statistical significance anymore,
indicating other risk factors besides rs10399805 to also
be relevant for disease development. The protective
effect of rs10399931[A] for asthma at 6 years, although
non-significant after adjusting for multiple testing
(Table 2), provided further evidence for the relevance
of genetic variation in CHI3L1 for asthma development.
This SNP was reportedly associated with asthma in
Taiwanese adults [27].
We observed a trend of association of increased YKL-40
levels with the OR for asthma at 6 years (Fig. 3). We
speculate that the low number of asthmatic subjects in
this study of unselected infants resulted in increasingly
large confidence intervals and, hence, our findings did
not reach formal significance level (Ptrend = 0.169). An
association of increased serum YKL-40 levels with
severe asthma in adult [6, 7] and paediatric subjects [5]
has been reported. Recent studies regarded YKL-40 as
not only a simple biomarker for asthma, but as directly
involved in airway remodeling. Increased YKL-40 levels
were associated with bronchial wall thickening on com-
puterised tomography in children with severe asthma
[5] and subepitehlial basement membrane thickness in
adults [4]. Mechanistically, Bara et al. showed that
YKL-40 increased bronchial smooth muscle cell prolif-
eration [8]. Despite emerging evidence for a direct in-
volvement of YKL-40 in asthma development, in this
study of unselected infants, YKL-40 in cord blood did
not serve as a predictor for asthma in early childhood.
Future studies will need to investigate if this was due to
the low level of asthmatics in the general population
and in our cohort.
Atopy
We identified a protective effect of the SNP rs10399931[A]
with atopy and positive prick test results, although non-
significant after correction for multiple testing. Several
studies investigated the association of genetic variation in
CHI3L1 with allergic diseases, but the SNP rs10399931 has
not been reported in that context. An association of
rs10399805 with atopy, recently reported in Korean
children (22), could not be confirmed in our study, possibly
due to differing study populations.
While there was no association of YKL-40 with atopy
and in two large population studies [4, 6], there was an
association of higher serum YKL-40 with allergic rhinitis
[28]. In our study, we observed a trend of association of
increased YKL-40 levels with the OR for atopy and posi-
tive prick (Ptrend = 0.188, Ptrend = 0.128). In conclusion,
we observed an association of genetic variation in
CHI3L1 and cord blood levels YKL-40 with allergic
diseases, but due to low sample size, this association did
not reach statistical significance.
Lung function
We did not find an association of genetic variation in
CHI3L1 and YKL-40 levels in cord blood with lung func-
tion measures at 5 weeks and 6 years. An association of
lung function measures with genetic variation in CHI3L1
and YKL-40 levels has been well described. Genetic
variation in CHI3L1 was associated with FEV1, FVC
and FEV1/FVC–ratios in adult European and Taiwanese
populations [4, 9, 27] and serum YKL-40 levels were
inversely associated with FEV1 in adult [4, 6, 7], but not
paediatric asthmatics [5]. We conclude from these find-
ings that in contrast to previous cross-sectional studies,
genetic variation in CHI3L1 and cord blood YKL-40
levels at birth are not associated with lung function
measures in unselected infants.
Relevance
From cross-sectional studies it is well known that both,
genetic variation in CHI3L1 and YKL-40 levels are asso-
ciated with asthma, atopy, and lung function measures.
Our study further explores this association since we
assessed genetic variation in CHI3L1 and YKL-40 in
cord blood within the setting of a cohort study before
the onset of these diseases. Moreover, our study is the
first to study this association in unselected, healthy in-
fants. The limited number of diseased subjects in the
general population and in this cohort study might be the
cause of the non-significant associations of YKL-40
with asthma, atopy, and prick test results. Studying
this association in a much larger cohort might result
in significant findings and reveal further insights for
the relevance of YKL-40 for these diseases.
Conclusion
In this prospective cohort study we found no robust
association between genetic variation in CHI3L1 and
asthma development, but found some indication that
rs10399805 might be related to asthma diagnosis at 6
years. In order to replicate findings of this study, and to
investigate its robustness, larger studies with a prospect-
ive design in an unselected population are warranted.
The trend of association between elevated cord blood
YKL-40 levels and asthma requires further validation
before YKL-40 may be considered an early biomarker
for asthma development in unselected infants.
Availability of data
Authors would be pleased to consider requests to share
original study data.
Usemann et al. BMC Pulmonary Medicine  (2016) 16:81 Page 8 of 9
Additional file
Additional file 1: Data S1. Methods. Figure S1. Flow chart of the
study population. Table S1. Potential risk factors of the study subjects.
Table S2. Characteristics and prevalence of the SNPs employed in this
study. Table S3. Associations between SNPs and cord blood YKL-40
levels. Table S4. Associations between SNPs and cord blood YKL-40
levels with weeks with any respiratory symptoms and weeks with se-
vere respiratory symptoms during the first year of life. Table S5. Associa-
tions between SNPs and cord blood YKL-40 levels with lung function at 5
weeks. Table S6. Associations between SNPs and cord blood YKL-40 levels
with positive prick test at school age. Table S7. Associations between SNPs
and cord blood YKL-40 levels with lung function at 6 years. (DOCX 197 kb)
Abbreviations
CHI3L1: chitinase-3-like-1; ELISA: enzyme-linked immunosorbent assay;
FEF25-75%: forced expiratory flow at 25-75% of FVC; FEV1: forced expiratory
volume in 1 second; FVC: forced vital capacity; LD: linkage disequilibrium;
MAF: minor allele frequency; LOD: logarithm of odds; V’E: minute ventilation;
SNPs: single nucleotide polymorphisms; TE: expiratory time; TPTEF: time to peak
tidal expiratory flow; VT: tidal volume; YKL-40: A 40 kilodalton chitinase-like pro-
tein named after the first three N-terminal amino; acids tyrosine (Y), lysine (K)
and leucine (L).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors contributed to the conception and design and to the revisions
and final approval of the manuscript. JU, PL, AS, IM, MR and DH performed
the data analysis and JU, PL, DH, MR and UF drafted the article. Clinical data
was collected and analysed by AS, PL and JU, YKL-40 measurements were
done by IM. UF is the primary investigator of the BILD cohort.
Acknowledgements
The authors thank all the study participants for participating in the study, the
study nurses Christine Becher and Monika Graf for performing the weekly
phone calls to the parents and the whole BILD cohort team. We thank
Karine Landgren Hugentobler for proofreading the manuscript.
This study was supported by the Swiss National Science Foundation grants
3200-B0-112099 and 324730_144280 to U. Frey and P. Latzin.
Author details
1University of Basel Children’s Hospital, University of Basel, Basel 4056,
Switzerland. 2Division of Respiratory Medicine, Department of Paediatrics,
Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
3Swiss Tropical and Public Health Institute Basel, Basel 4051, Switzerland.
4University of Basel, Basel 4003, Switzerland. 5Children’s Hospital, University of
Tuebingen, Tuebingen 72076, Germany.
Received: 11 December 2015 Accepted: 1 May 2016
References
1. Global strategy for asthma management and prevention. http://ginasthma.
org/. Accessed Dec 2015.
2. Hartl D, Lee CG, Da Silva CA, Chupp GL, Elias JA. Novel biomarkers in
asthma: chemokines and chitinase-like proteins. Curr Opin Allergy Clin
Immunol. 2009;9:60–6.
3. Bleau G, Massicotte F, Merlen Y, Boisvert C. Mammalian chitinase-like
proteins. EXS. 1999;87:211–21.
4. Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, Dziura JD, Reed J,
Coyle AJ, Kiener P, et al. A chitinase-like protein in the lung and circulation
of patients with severe asthma. N Engl J Med. 2007;357:2016–27.
5. Konradsen JR, James A, Nordlund B, Reinius LE, Soderhall C, Melen E,
Wheelock AM, Lodrup Carlsen KC, Lidegran M, Verhoek M, et al. The
chitinase-like protein YKL-40: a possible biomarker of inflammation and
airway remodeling in severe pediatric asthma. J Allergy Clin Immunol.
2013;132:328–35. e325.
6. Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, Radford S, Parry RR,
Heinzmann A, Deichmann KA, et al. Effect of variation in CHI3L1 on serum YKL-40
level, risk of asthma, and lung function. N Engl J Med. 2008;358:1682–91.
7. Tang H, Fang Z, Sun Y, Li B, Shi Z, Chen J, Zhang T, Xiu Q. YKL-40 in
asthmatic patients, and its correlations with exacerbation, eosinophils and
immunoglobulin E. Eur Respir J. 2010;35:757–60.
8. Bara I, Ozier A, Girodet PO, Carvalho G, Cattiaux J, Begueret H, Thumerel M,
Ousova O, Kolbeck R, Coyle AJ, et al. Role of YKL-40 in bronchial smooth
muscle remodeling in asthma. Am J Respir Crit Care Med. 2012;185:715–22.
9. Gomez JL, Crisafi GM, Holm CT, Meyers DA, Hawkins GA, Bleecker ER, Jarjour N,
Severe Asthma Research Program I, Cohn L, Chupp GL. Genetic variation in
chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway
expression of YKL-40. J Allergy Clin Immunol. 2015.
10. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of
LD and haplotype maps. Bioinformatics. 2005;21:263–5.
11. Latzin P, Frey U, Roiha HL, Baldwin DN, Regamey N, Strippoli MP, Zwahlen M,
Kuehni CE, Swiss Paediatric Respiratory Research G. Prospectively assessed
incidence, severity, and determinants of respiratory symptoms in the first year
of life. Pediatr Pulmonol. 2007;42:41–50.
12. Silverman M, Wang M, Hunter G, Taub N. Episodic viral wheeze in preschool
children: effect of topical nasal corticosteroid prophylaxis. Thorax. 2003;58:431–4.
13. Frey U, Stocks J, Coates A, Sly P, Bates J. Specifications for equipment used
for infant pulmonary function testing. ERS/ATS Task Force on Standards for
Infant Respiratory Function Testing. European Respiratory Society/American
Thoracic Society. Eur Respir J. 2000;16:731–40.
14. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, Mitchell EA,
Pearce N, Sibbald B, Stewart AW, et al. International Study of Asthma and
Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J.
1995;8:483–91.
15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R,
Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of
spirometry. Eur Respir J. 2005;26:319–38.
16. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL,
Hankinson JL, Ip MS, Zheng J, et al. Multi-ethnic reference values for
spirometry for the 3-95-years age range: the global lung function 2012
equations. Eur Respir J. 2012;40:1324–43.
17. Fuchs O, Latzin P, Thamrin C, Stern G, Frischknecht P, Singer F, Kieninger E,
Proietti E, Riedel T, Frey U. Normative data for lung function and exhaled
nitric oxide in unsedated healthy infants. Eur Respir J. 2011;37:1208–16.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J Roy Stat Soc B. 1995;57:12.
19. Team RDC. R: A Language and Environment for Statistical Computing. 2012
20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
Sklar P, de Bakker PI, Daly MJ, et al. PLINK: a tool set for whole-genome
association and population-based linkage analyses. Am J Hum Genet. 2007;
81:559–75.
21. Quanto 1.1: A computer Programm for power and sample size calculations
for genetic-epidemiology studies. http://biostats.usc.edu/Quanto.html.
Accessed Dec 2015.
22. Rathcke CN, Holmkvist J, Husmoen LL, Hansen T, Pedersen O, Vestergaard H,
Linneberg A. Association of polymorphisms of the CHI3L1 gene with
asthma and atopy: a populations-based study of 6514 Danish adults. PLoS
One. 2009;4, e6106.
23. Sohn MH, Lee JH, Kim KW, Kim SW, Lee SH, Kim KE, Kim KH, Lee CG, Elias JA,
Lee MG. Genetic variation in the promoter region of chitinase 3-like 1 is
associated with atopy. Am J Respir Crit Care Med. 2009;179:449–56.
24. Sennhauser FH, Kuhni CE. Prevalence of respiratory symptoms in Swiss
children: is bronchial asthma really more prevalent in boys? Pediatr
Pulmonol. 1995;19:161–6.
25. Fuchs O, Latzin P, Kuehni CE, Frey U. Cohort profile: the Bern infant lung
development cohort. Int J Epidemiol. 2012;41:366–76.
26. Wu AC, Lasky-Su J, Rogers CA, Klanderman BJ, Litonjua A. Polymorphisms of
chitinases are not associated with asthma. J Allergy Clin Immunol. 2010;125:
754–7. 757 e751-757 e752.
27. Tsai Y, Ko Y, Huang M, Lin M, Wu C, Wang C, Chen Y, Li J, Tseng Y, Wang T.
CHI3L1 polymorphisms associate with asthma in a Taiwanese population. BMC
Med Genet. 2014;15:86.
28. Kwon JW, Kim TW, Cho SH, Min KU, Park HW. Serum YKL-40 levels are
correlated with symptom severity in patients with allergic rhinitis. Allergy.
2011;66:1252–3.
Usemann et al. BMC Pulmonary Medicine  (2016) 16:81 Page 9 of 9
